{"id":"propranolol-spironolactone","safety":{"commonSideEffects":[{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Hyperkalemia"},{"rate":null,"effect":"Bradycardia"},{"rate":null,"effect":"Sexual dysfunction"},{"rate":null,"effect":"Gynecomastia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Propranolol blocks beta-adrenergic receptors, decreasing cardiac output and renin release, thereby lowering blood pressure and heart rate. Spironolactone antagonizes aldosterone at mineralocorticoid receptors in the collecting duct, promoting sodium and water excretion while conserving potassium. Together, they provide complementary cardiovascular and diuretic effects with potassium-sparing properties.","oneSentence":"This combination uses propranolol (a beta-blocker) to reduce heart rate and blood pressure, and spironolactone (an aldosterone antagonist) to promote sodium and water excretion while retaining potassium.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:03:08.975Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"},{"name":"Heart failure with reduced ejection fraction"},{"name":"Post-myocardial infarction management"}]},"trialDetails":[{"nctId":"NCT04467931","phase":"","title":"ACEI or ARB and COVID-19 Severity and Mortality in US Veterans","status":"COMPLETED","sponsor":"University of Utah","startDate":"2020-01-19","conditions":"Hypertension, COVID","enrollment":22213},{"nctId":"NCT00188045","phase":"PHASE4","title":"Hemodynamic Effects of Chronic Administration of Spironolactone and/or Propranolol in Alcoholic Cirrhotic Patients","status":"TERMINATED","sponsor":"University Hospital, Angers","startDate":"1995-04","conditions":"Alcoholic Cirrhosis","enrollment":54},{"nctId":"NCT00332904","phase":"PHASE4","title":"Effect of Betablocker or Aldosterone Antagonist Therapy on Patients With Liver Cirrhosis","status":"UNKNOWN","sponsor":"Hvidovre University Hospital","startDate":"2006-08","conditions":"Liver Cirrhosis, Portal Hypertension","enrollment":22},{"nctId":"NCT00701792","phase":"NA","title":"Liver Transplantation Versus Alternative Therapies for Patients With Pugh B Alcoholic Cirrhosis","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Besancon","startDate":"1994-03","conditions":"Cirrhosis","enrollment":120},{"nctId":"NCT00684489","phase":"NA","title":"Renin-Guided Therapeutics in the Management of Untreated, Uncontrolled, or Complicated Hypertension","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2003-09","conditions":"Hypertension","enrollment":52}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"AGGRESSION"},{"count":1,"reaction":"AGITATION"}],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Propranolol - Spironolactone","genericName":"Propranolol - Spironolactone","companyName":"University Hospital, Angers","companyId":"university-hospital-angers","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination uses propranolol (a beta-blocker) to reduce heart rate and blood pressure, and spironolactone (an aldosterone antagonist) to promote sodium and water excretion while retaining potassium. Used for Hypertension, Heart failure with reduced ejection fraction, Post-myocardial infarction management.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}